Arvinas (ARVN) Net Income towards Common Stockholders (2017 - 2026)
Arvinas' (ARVN) quarterly Net Income towards Common Stockholders came in at -$57.6 million in Q1 2026, down 169.48% year-on-year from $82.9 million in Q1 2025, and up 14.54% quarter-over-quarter from -$67.4 million in Q4 2025.
Arvinas (ARVN) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
Arvinas' Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$57.6 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 169.48% year-over-year to -$57.6 million in Q1 2026; TTM through Mar 2026 was -$221.3 million, a 374.89% decrease from a year earlier, with the FY2025 full-year figure at -$80.8 million, up 59.38% from the prior year.
- Net Income towards Common Stockholders grew to -$57.6 million in Q1 2026 per ARVN's latest filing, from -$67.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $82.9 million in Q1 2025 and bottomed at -$154.8 million in Q4 2023.
- The 5-year median for Net Income towards Common Stockholders is -$63.3 million (2022), against an average of -$57.3 million.
- Across the five-year window, Net Income towards Common Stockholders surged 219.45% in 2025 and sank 169.48% in 2026, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$80.1 million in 2022, then slumped by 93.26% to -$154.8 million in 2023, then jumped by 70.87% to -$45.1 million in 2024, then plunged by 49.45% to -$67.4 million in 2025, then advanced by 14.54% to -$57.6 million in 2026.
- Per Business Quant, the three latest ARVN Net Income towards Common Stockholders figures stand at -$57.6 million (Q1 2026), -$67.4 million (Q4 2025), and -$35.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Arvinas | 529.92 Mn | -84.98 Mn | - | -57.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.60 Mn |
| Dec 31, 2025 | -67.40 Mn |
| Sep 30, 2025 | -35.10 Mn |
| Jun 30, 2025 | -61.20 Mn |
| Mar 31, 2025 | 82.90 Mn |
| Dec 31, 2024 | -45.10 Mn |
| Sep 30, 2024 | -49.20 Mn |
| Jun 30, 2024 | -35.20 Mn |
| Mar 31, 2024 | -69.40 Mn |
| Dec 31, 2023 | -154.80 Mn |
| Sep 30, 2023 | -63.90 Mn |
| Jun 30, 2023 | -65.30 Mn |
| Mar 31, 2023 | -80.80 Mn |
| Dec 31, 2022 | -80.10 Mn |
| Sep 30, 2022 | -63.30 Mn |
| Jun 30, 2022 | -67.50 Mn |
| Mar 31, 2022 | -61.10 Mn |
| Dec 31, 2021 | -46.10 Mn |
| Sep 30, 2021 | -46.80 Mn |
| Jun 30, 2021 | -50.30 Mn |